{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T01:19:05Z","timestamp":1794187145966,"version":"4.8.0"},"reference-count":465,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jhep.2022.05.011","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T21:16:42Z","timestamp":1655759802000},"page":"761-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":410,"title":["EASL Clinical Practice Guidelines on sclerosing cholangitis"],"prefix":"10.1016","volume":"77","author":[{"given":"Olivier","family":"Chazouilleres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Hemming","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Samyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.05.011_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.21405","article-title":"Sclerosing cholangitis: a focus on secondary causes","volume":"44","author":"Abdalian","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/2050640620934911","article-title":"European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations","volume":"8","author":"Lohr","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2022.05.011_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2016.06.021","article-title":"Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease","volume":"151","author":"Lunder","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib6","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib7","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and\u00a0outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/apt.14393","article-title":"Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients","volume":"47","author":"Nordenvall","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial","volume":"40","author":"Farkkila","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib12","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2020.12.058","article-title":"Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis","volume":"160","author":"Kummen","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrgastro.2016.154","article-title":"Genetics of primary sclerosing cholangitis and pathophysiological implications","volume":"14","author":"Jiang","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.05.011_bib16","first-page":"43","article-title":"Surgical pathology of the syndrome of primary sclerosing cholangitis","volume":"13","author":"Ludwig","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2022.05.011_bib17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00535-018-1484-9","article-title":"Clinical guidelines for primary sclerosing cholangitis 2017","volume":"53","author":"Isayama","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2015","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib22","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2018.10.011","article-title":"Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability","volume":"70","author":"Cornberg","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-0039-1687853","article-title":"Magnetic resonance imaging in primary sclerosing cholangitis-current state and future directions","volume":"39","author":"Zenouzi","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib26","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.29293","article-title":"Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group","volume":"66","author":"Schramm","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiol.10091953","article-title":"Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography","volume":"256","author":"Dave","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2022.05.011_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.20287","article-title":"Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis","volume":"40","author":"Talwalkar","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-2007-966253","article-title":"The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis","volume":"39","author":"Meagher","year":"2007","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2022.05.011_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1148\/radiology.215.1.r00ap2671","article-title":"Primary sclerosing cholangitis: evaluation with\u00a0MR\u00a0cholangiography-a case-control study","volume":"215","author":"Fulcher","year":"2000","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2022.05.011_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.gie.2005.12.034","article-title":"Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography","volume":"64","author":"Moff","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00330-021-08147-7","article-title":"Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group","volume":"32","author":"Venkatesh","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2008-1040417","article-title":"Small-duct primary sclerosing cholangitis","volume":"11","author":"Ludwig","year":"1991","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0168-8278(02)00085-5","article-title":"Small duct primary sclerosing cholangitis","volume":"36","author":"Chapman","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study Group consensus process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2559.2011.03853.x","article-title":"Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation","volume":"60","author":"Portmann","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.jhep.2022.05.011_bib37","article-title":"Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas","volume":"3","author":"Hubers","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.05.011_bib38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.26999","article-title":"Exposure to occupational antigens might predispose to IgG4-related disease","volume":"60","author":"de Buy Wenniger","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2214\/AJR.12.10360","article-title":"Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis","volume":"202","author":"Tokala","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhep.2022.05.011_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CEG.S115518","article-title":"Secondary sclerosing cholangitis in critically ill patients: current perspectives","volume":"10","author":"Gudnason","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib42","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","article-title":"Autoantibodies in primary sclerosing cholangitis","volume":"14","author":"Hov","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaut.2018.10.004","article-title":"The clinical usage and definition of autoantibodies in immune-mediated liver disease: a comprehensive overview","volume":"95","author":"Terziroli Beretta-Piccoli","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jhep.2022.05.011_bib44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2022.05.011_bib45","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0168-8278(05)80604-X","article-title":"A\u00a02-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment","volume":"21","author":"Lo","year":"1994","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib46","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0168-8278(00)80241-X","article-title":"Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases","volume":"32","author":"Roozendaal","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib47","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3109\/00365521.2013.825313","article-title":"Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis","volume":"48","author":"Lenzen","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib48","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/liv.13238","article-title":"Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis","volume":"37","author":"Hov","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib49","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/apt.16153","article-title":"Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis","volume":"53","author":"Wunsch","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gutjnl-2016-311739","article-title":"Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis","volume":"66","author":"Jendrek","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib52","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1007\/s00261-020-02572-w","article-title":"Magnetic resonance imaging features of small-duct primary sclerosing cholangitis","volume":"45","author":"Kozaka","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.jhep.2022.05.011_bib53","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/liv.12492","article-title":"Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease","volume":"34","author":"Naess","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.51.5.731","article-title":"Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis","volume":"51","author":"Bjornsson","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0168-8278(02)00036-3","article-title":"Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC)","volume":"36","author":"Broome","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib56","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/jhep.2002.33202","article-title":"Small-duct primary sclerosing cholangitis: a long-term follow-up study","volume":"35","author":"Angulo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib57","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"Bjornsson","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib58","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep4.1467","article-title":"Primary sclerosing cholangitis with features of autoimmune hepatitis: exploring the global variation in management","volume":"4","author":"Milkiewicz","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.05.011_bib60","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2036.2012.05223.x","article-title":"Review article: overlap syndromes and autoimmune liver disease","volume":"36","author":"Trivedi","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib61","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0168-8278(00)80004-5","article-title":"Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system","volume":"33","author":"Kaya","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1034\/j.1600-0641.2000.033004543.x","article-title":"High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis","volume":"33","author":"van Buuren","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib64","first-page":"15","article-title":"Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis","volume":"80","author":"Hunter","year":"2011","journal-title":"Ulster Med J"},{"key":"10.1016\/j.jhep.2022.05.011_bib65","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejim.2008.06.004","article-title":"High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis","volume":"20","author":"Olsson","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib66","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib67","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","article-title":"Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"100","author":"Floreani","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib68","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2014.08.002","article-title":"Long-term outcome in PSC\/AIH \"overlap syndrome\": does immunosuppression also treat the PSC component?","volume":"61","author":"Zenouzi","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/hep.24487","article-title":"Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma","volume":"54","author":"Oseini","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib70","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.26977","article-title":"Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis","volume":"59","author":"Boonstra","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajg.2016.40","article-title":"Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort","volume":"111","author":"Culver","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib72","article-title":"IgG4\/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer","volume":"2","author":"de Vries","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.05.011_bib73","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","article-title":"Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis","volume":"101","author":"Mendes","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib74","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.dld.2014.06.010","article-title":"The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis","volume":"46","author":"Benito de Valle","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib75","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.05.011_bib76","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","article-title":"Primary sclerosing cholangitis: natural history,\u00a0prognostic factors and survival analysis","volume":"10","author":"Wiesner","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib78","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"de Vries","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib79","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","volume":"19","author":"Trivedi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib80","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib82","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib83","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib84","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164224","article-title":"Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in primary sclerosing cholangitis","volume":"11","author":"Ehlken","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.05.011_bib86","series-title":"The Liver Meeting 2019. Boston, Massachusetts, USA","first-page":"33A","article-title":"Prospective validation of the prognostic value of liver stiffness (LS) assessed by fibroscan in primary sclerosing cholangitis (PSC): interim analysis of the ficus study","author":"Chazouill\u00e8res","year":"2019"},{"key":"10.1016\/j.jhep.2022.05.011_bib87","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib88","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib90","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41395-018-0265-7","article-title":"Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis","volume":"114","author":"Moctezuma-Velazquez","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib91","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cgh.2019.10.041","article-title":"Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis","volume":"18","author":"Eaton","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib92","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.51.4.562","article-title":"Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population","volume":"51","author":"Ponsioen","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib93","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib94","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","article-title":"Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib95","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis","volume":"51","author":"Rudolph","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib96","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.14309\/ajg.0000000000000461","article-title":"The complementary value of magnetic resonance imaging and vibration-controlled transient elastography for risk stratification in primary sclerosing cholangitis","volume":"114","author":"Cazzagon","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib97","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jmri.27113","article-title":"Quantitative MRCP imaging: accuracy, repeatability, reproducibility, and cohort-derived normative ranges","volume":"52","author":"Goldfinger","year":"2020","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jhep.2022.05.011_bib98","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/0016-5085(91)90673-9","article-title":"Natural history and prognostic variables in primary sclerosing cholangitis","volume":"100","author":"Farrant","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib99","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis","volume":"38","author":"Broome","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib100","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A\u00a0revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2022.05.011_bib101","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/jhep.2002.31872","article-title":"Time-dependent Cox regression model is superior in prediction of\u00a0prognosis in primary sclerosing cholangitis","volume":"35","author":"Boberg","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib102","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A\u00a0novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"de Vries","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib103","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib104","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/hep.30085","article-title":"Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes of the disease: a derivation and validation study using machine learning","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib105","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis","volume":"71","author":"Goet","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib106","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2019.08.013","article-title":"Risk stratification in primary sclerosing cholangitis: it's time to move on from replicating imperfection and break the glass ceiling","volume":"71","author":"Trivedi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib107","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib108","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.28128","article-title":"Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists","volume":"63","author":"Trivedi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib109","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.27180","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)","volume":"60","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib110","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/hep.22577","article-title":"Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis","volume":"48","author":"Millonig","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib111","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.26620","article-title":"Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression","volume":"59","author":"Ruiz","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109884","article-title":"Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis","volume":"142","author":"Grigoriadis","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib113","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00330-021-08142-y","article-title":"Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores","volume":"32","author":"Ismail","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib114","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib115","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib116","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/hep.31575","article-title":"Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis","volume":"73","author":"Eaton","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib117","series-title":"The International Liver Congress. (digital congress): J Hepatol","first-page":"S227","article-title":"Hepatobiliary malignancy surveillance strategies in primary sclerosing cholangitis associate with reduced mortality","author":"Bergquist","year":"2021"},{"key":"10.1016\/j.jhep.2022.05.011_bib118","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.22441","article-title":"Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis","volume":"48","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib119","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.cgh.2019.07.011","article-title":"AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: expert review","volume":"17","author":"Bowlus","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib120","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.24570","article-title":"Cancer surveillance in patients with primary sclerosing cholangitis","volume":"54","author":"Razumilava","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib121","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1055-9965.EPI-20-1241","article-title":"Hepatobiliary cancer risk in patients with inflammatory bowel disease: a scandinavian population-based cohort study","volume":"30","author":"Erichsen","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhep.2022.05.011_bib122","series-title":"The Liver Meeting; 2021","first-page":"1","article-title":"Population-based prospective surveillance of patients with primary sclerosing cholangitis (PSC) for early detection of cholangiocarcinoma","author":"Villard","year":"2021"},{"key":"10.1016\/j.jhep.2022.05.011_bib123","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib124","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0168-8278(99)80198-6","article-title":"A\u00a03-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"30","author":"Hultcrantz","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/apt.15146","article-title":"Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis","volume":"49","author":"Wannhoff","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s10620-012-2401-3","article-title":"Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma","volume":"58","author":"Venkatesh","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib127","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2013.08.005","article-title":"FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"59","author":"Wannhoff","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib128","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","article-title":"The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis","volume":"50","author":"Levy","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib129","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cgh.2015.07.014","article-title":"Inflammation but not biliary obstruction is associated with carbohydrate antigen 19-9 levels in patients with primary sclerosing cholangitis","volume":"13","author":"Wannhoff","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/liv.12640","article-title":"Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography","volume":"35","author":"von Seth","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib131","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0041-110792","article-title":"Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia","volume":"48","author":"Boyd","year":"2016","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2022.05.011_bib132","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.cgh.2014.02.008","article-title":"Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis","volume":"12","author":"Zenouzi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib133","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1478-3231.2011.02614.x","article-title":"Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort","volume":"32","author":"de Valle","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib134","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib135","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1572-0241.2002.05677.x","article-title":"In primary sclerosing cholangitis, gallbladder polyps are frequently malignant","volume":"97","author":"Buckles","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib136","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.11.019","article-title":"Gallbladder disease in patients with primary sclerosing cholangitis","volume":"48","author":"Said","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib137","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.jhep.2022.05.011_bib138","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib139","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2010.10.014","article-title":"Bone disease in patients with primary sclerosing cholangitis","volume":"140","author":"Angulo","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib140","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jhep.2018.12.035","article-title":"Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis","volume":"70","author":"Schmidt","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib141","first-page":"895","article-title":"Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry","volume":"36","author":"Guichelaar","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib142","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1478-3231.2005.01075.x","article-title":"Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis","volume":"25","author":"Campbell","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib143","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.21805","article-title":"Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors","volume":"46","author":"Guichelaar","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib144","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1872-034X.2009.00527.x","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials","volume":"39","author":"Shi","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2022.05.011_bib146","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib147","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(90)90281-U","article-title":"Ursodeoxycholic acid for primary sclerosing cholangitis","volume":"11","author":"Chazouilleres","year":"1990","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib148","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/hep.1840140516","article-title":"Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study","volume":"14","author":"O'Brien","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib149","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","article-title":"Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period","volume":"20","author":"Stiehl","year":"1994","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib150","first-page":"1472","article-title":"Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period","volume":"43","author":"De Maria","year":"1996","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib151","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group","volume":"336","author":"Lindor","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib152","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","article-title":"Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses","volume":"29","author":"van Hoogstraten","year":"1998","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib153","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","article-title":"A\u00a0preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis","volume":"121","author":"Mitchell","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib154","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","article-title":"High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis","volume":"96","author":"Harnois","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib155","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib156","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib157","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/gast.2002.35948","article-title":"Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles","volume":"123","author":"Fickert","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib158","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.23631","article-title":"Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression","volume":"52","author":"Sinakos","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib159","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib161","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib162","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep4.1421","article-title":"A\u00a0prospective trial of withdrawal and reinstitution of ursodeoxycholic acid in pediatric primary sclerosing cholangitis","volume":"3","author":"Black","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.05.011_bib163","first-page":"74a","article-title":"The association of Udca treatment with long-term outcome and biliary tract cancer in patients with primary sclerosing cholangitis","volume":"72","author":"Arizumi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib164","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","article-title":"Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"124","author":"Pardi","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","article-title":"Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"134","author":"Tung","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib166","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2036.2005.02650.x","article-title":"The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis","volume":"22","author":"Wolf","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib167","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2011.04966.x","article-title":"High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia","volume":"35","author":"Lindstrom","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib168","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib169","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10620-013-2772-0","article-title":"Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis","volume":"58","author":"Hansen","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib170","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/MIB.0b013e318286fa61","article-title":"Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib171","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MEG.0b013e3281108068","article-title":"The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid","volume":"19","author":"Rudolph","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib172","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jhep.2004.01.002","article-title":"Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy","volume":"40","author":"Brandsaeter","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib173","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib174","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib175","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib176","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib177","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib178","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib179","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib180","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib181","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib182","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib183","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib184","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/00365520310005172","article-title":"Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients","volume":"38","author":"Boberg","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140525","article-title":"Criteria used in clinical practice to guide immunosuppressive treatment in patients with primary sclerosing cholangitis","volume":"10","author":"Schulze","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.05.011_bib186","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jhep.2020.07.027","article-title":"Long-term outcome in PSC patients receiving azathioprine: does immunosuppression have a positive effect on survival?","volume":"73","author":"Creutzfeldt","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib187","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.cgh.2016.07.032","article-title":"No evidence that azathioprine increases risk of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"14","author":"Zenouzi","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib188","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cgh.2012.01.025","article-title":"Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis","volume":"10","author":"Benito de Valle","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib189","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MJT.0b013e3181c9dac6","article-title":"Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy","volume":"18","author":"Bjornsson","year":"2011","journal-title":"Am J Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib190","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2018.05.018","article-title":"Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice","volume":"69","author":"Guicciardi","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib191","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/liv.13698","article-title":"Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents","volume":"38","author":"Yu","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib192","article-title":"Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study","author":"Eksteen","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.05.011_bib193","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/s-0036-1594007","article-title":"The microbiome and primary sclerosing cholangitis","volume":"36","author":"Ali","year":"2016","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib194","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/liv.13979","article-title":"Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis","volume":"39","author":"Dhillon","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib195","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/lt.25882","article-title":"Variation in bile microbiome by the etiology of cholestatic liver disease","volume":"26","author":"Tyc","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib196","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/389537","article-title":"Role of the microbiota and antibiotics in primary sclerosing cholangitis","volume":"2013","author":"Tabibian","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib197","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.14540","article-title":"Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis","volume":"47","author":"Damman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib198","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib199","doi-asserted-by":"crossref","first-page":"26757","DOI":"10.18632\/oncotarget.5610","article-title":"A\u00a0network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis","volume":"6","author":"Zhu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2022.05.011_bib200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A\u00a0triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib201","article-title":"Oral vancomycin, ursodeoxycholic acid or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","author":"Deneau","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10875-012-9801-1","article-title":"Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis","volume":"33","author":"Abarbanel","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jhep.2022.05.011_bib203","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib204","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0140-6736(59)90098-4","article-title":"The liver in ulcerative colitis; treatment of pericholangitis with tetracycline","volume":"2","author":"Rankin","year":"1959","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.05.011_bib205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/imj.1965.14.4.286","article-title":"Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis","volume":"14","author":"Mistilis","year":"1965","journal-title":"Australas Ann Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib206","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib207","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/039463200702000423","article-title":"Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation","volume":"20","author":"Boner","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jhep.2022.05.011_bib208","article-title":"Potential association of doxycycline with the onset of primary sclerosing cholangitis: a case series","author":"Buness","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib209","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/gut.2005.077461","article-title":"Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers","volume":"55","author":"Rust","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib210","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00535-005-1758-x","article-title":"Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis","volume":"41","author":"Tada","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib211","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1440-1746.1998.tb00740.x","article-title":"Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine","volume":"13","author":"Kozaiwa","year":"1998","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib212","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib213","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib214","first-page":"738a","article-title":"Broad host range bacteriophage for reduction of Klebsiella pneumoniae as potential therapy in primary sclerosing cholangitis","volume":"72","author":"Kahan-Hanum","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib215","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"66","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib216","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib217","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib218","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2362.2000.00606.x","article-title":"Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man","volume":"30","author":"Rust","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jhep.2022.05.011_bib219","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates\u00a0for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib220","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib221","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib222","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jhbp.512","article-title":"Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos)","volume":"25","author":"Kiriyama","year":"2018","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib223","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","article-title":"The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis","volume":"102","author":"Kaplan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib224","first-page":"1504","article-title":"Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis--a study of bile cultures from ERCP","volume":"47","author":"Bjornsson","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib225","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(69)91802-9","article-title":"Portal bacteraemia in cases of ulcerative colitis submitted to colectomy","volume":"1","author":"Eade","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.05.011_bib226","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/00365529409103625","article-title":"Etiology and pathogenesis in primary sclerosing cholangitis","volume":"204","author":"Boberg","year":"1994","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.jhep.2022.05.011_bib227","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00042737-200601000-00012","article-title":"The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis","volume":"18","author":"Pohl","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib228","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","article-title":"No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis","volume":"155","author":"Ponsioen","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib229","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1055\/s-0032-1325677","article-title":"Risk factors for complications of ERCP in primary sclerosing cholangitis","volume":"44","author":"Ismail","year":"2012","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2022.05.011_bib230","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.gie.2014.06.030","article-title":"ERCP-related adverse events in patients with primary sclerosing cholangitis","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib231","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jhbp.496","article-title":"Indications and techniques of biliary drainage for acute cholangitis in updated Tokyo Guidelines 2018","volume":"24","author":"Mukai","year":"2017","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib232","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jhbp.519","article-title":"Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis","volume":"25","author":"Mayumi","year":"2018","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib233","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jhbp.518","article-title":"Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis","volume":"25","author":"Gomi","year":"2018","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib234","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.3748\/wjg.v18.i27.3585","article-title":"Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients","volume":"18","author":"Kaya","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib235","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0168-8278(98)80316-4","article-title":"Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers","volume":"28","author":"Olsson","year":"1998","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib236","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000493579","article-title":"Endoscopic retrograde cholangio-pancreatography-obtained bile culture can guide antibiotic therapy in acute cholangitis","volume":"37","author":"Chandra","year":"2019","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib237","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0016-5107(02)70365-9","article-title":"Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis","volume":"56","author":"Rerknimitr","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib238","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00534-006-1154-9","article-title":"Techniques of biliary drainage for acute cholangitis: Tokyo Guidelines","volume":"14","author":"Tsuyuguchi","year":"2007","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib239","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2006.07.022","article-title":"Biliary candida infections in primary sclerosing cholangitis","volume":"45","author":"Kulaksiz","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib240","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s12879-014-0562-8","article-title":"Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis","volume":"14","author":"Rupp","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib241","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.12663","article-title":"Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis","volume":"39","author":"Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib242","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib243","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1600-6143.2011.03969.x","article-title":"Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis","volume":"12","author":"Goldberg","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib244","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/lt.23587","article-title":"Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis","volume":"19","author":"Goldberg","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib245","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/TXD.0000000000000548","article-title":"Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway","volume":"1","author":"Andersen","year":"2015","journal-title":"Transpl Direct"},{"key":"10.1016\/j.jhep.2022.05.011_bib246","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0040-1708806","article-title":"Noninvasive diagnostics for portal hypertension: a comprehensive review","volume":"40","author":"Mandorfer","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib247","article-title":"Measurement of the hepatic venous pressure gradient and transjugular liver biopsy","author":"Reiberger","year":"2020","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.jhep.2022.05.011_bib248","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.20029","article-title":"Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis","volume":"39","author":"Zein","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib249","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.23432","article-title":"The predictors of the presence of varices in patients\u00a0with primary sclerosing cholangitis","volume":"51","author":"Treeprasertsuk","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib250","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2013.02.016","article-title":"Primary sclerosing cholangitis: diagnosis, prognosis, and management","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib251","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/01.pas.0000213286.65907.ea","article-title":"Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy","volume":"30","author":"Abraham","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2022.05.011_bib252","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib253","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib254","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib255","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib256","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12072-017-9807-0","article-title":"Impact of etiological treatment on prognosis","volume":"12","author":"Su","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib257","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib258","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib259","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib260","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0016-5085(86)90926-1","article-title":"Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis","volume":"90","author":"Wiesner","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib261","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0025-6196(11)64839-8","article-title":"Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy","volume":"71","author":"Kartheuser","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2022.05.011_bib262","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/BF02050064","article-title":"Bleeding from peristomal varices: perspectives on prevention and treatment","volume":"34","author":"Fucini","year":"1991","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jhep.2022.05.011_bib263","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00000658-199304000-00002","article-title":"Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis","volume":"217","author":"Kartheuser","year":"1993","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib264","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0016-5107(90)71117-0","article-title":"The role of endoscopic injection sclerotherapy in the management of bleeding peristomal varices","volume":"36","author":"Wolfsen","year":"1990","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib265","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s00270-020-02462-0","article-title":"Endovenous cyanoacrylate-lipiodol embolisation of peristomal varices by direct puncture under ultrasound guidance in a critically ill patient with recurrent, large-volume peristomal variceal haemorrhage","volume":"43","author":"Dolan","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib266","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00270-009-9536-4","article-title":"Direct percutaneous embolization of bleeding stomal varices","volume":"33","author":"Naidu","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib267","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jvir.2011.01.437","article-title":"Obliteration of bleeding peristomal varices with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam","volume":"22","author":"Teo","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib268","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.27925","article-title":"A\u00a0novel, minimally invasive technique for management of peristomal varices","volume":"63","author":"Tabibian","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib269","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1023\/A:1018850910271","article-title":"Transjugular portosystemic shunt for treatment of bleeding stomal varices","volume":"42","author":"Johnson","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib270","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00005176-199405000-00020","article-title":"Treatment of bleeding stomal varices using transjugular intrahepatic portosystemic shunt","volume":"18","author":"Lagier","year":"1994","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2022.05.011_bib271","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1148\/radiology.170.3.2783784","article-title":"Stomal varices: percutaneous transhepatic embolization","volume":"170","author":"Samaraweera","year":"1989","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2022.05.011_bib272","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1007\/s00270-020-02506-5","article-title":"Trans-splenic embolization of peristomal varices in the setting of non-cirrhotic portal hypertension: an under-recognized technique","volume":"43","author":"Purushothaman","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2022.05.011_bib273","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.diii.2018.08.017","article-title":"Treatment of peristomal hemorrhage: a review of outcomes and comparison of two minimally invasive techniques","volume":"99","author":"Young","year":"2018","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.jhep.2022.05.011_bib274","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM200102083440604","article-title":"Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct","volume":"344","author":"Hammel","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.05.011_bib275","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gie.2009.10.041","article-title":"Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment","volume":"71","author":"Gotthardt","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib276","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202686","article-title":"Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis","volume":"13","author":"Peiseler","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.05.011_bib277","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ajg.2008.161","article-title":"Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis","volume":"104","author":"Bangarulingam","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib278","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1572-0241.2001.03690.x","article-title":"Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis","volume":"96","author":"Kaya","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib279","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","article-title":"Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis","volume":"68","author":"Rupp","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib280","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MPA.0000000000000044","article-title":"Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis","volume":"43","author":"Buijs","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.jhep.2022.05.011_bib281","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib282","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0038-1667299","article-title":"ABCB4 gene aberrations in human liver disease: an evolving spectrum","volume":"38","author":"Reichert","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib283","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0016-5085(03)00898-9","article-title":"ABCB4 gene mutation-associated cholelithiasis in adults","volume":"125","author":"Rosmorduc","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib284","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1111\/liv.14662","article-title":"Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma","volume":"40","author":"de Vries","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","article-title":"Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland","volume":"55","author":"Barner-Rasmussen","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib286","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90175-w","article-title":"Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies","volume":"11","author":"Aune","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.05.011_bib287","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s10620-006-9681-4","article-title":"Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"52","author":"Fevery","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib288","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","article-title":"Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis","volume":"99","author":"Burak","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib289","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation","volume":"37","author":"Boberg","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib290","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib291","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.510310103","article-title":"Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study","volume":"31","author":"Chalasani","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib292","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/hep.510270201","article-title":"Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study","volume":"27","author":"Bergquist","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib293","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience","volume":"24","author":"Chapman","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib294","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1055\/s-0043-107029","article-title":"Role of endoscopy in primary sclerosing cholangitis: European society of gastrointestinal endoscopy (ESGE) and European association for the study of the liver (EASL) clinical guideline","volume":"49","author":"Aabakken","year":"2017","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2022.05.011_bib295","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5114\/ceh.2020.93054","article-title":"Diagnostic yield of magnetic resonance imaging for cholangiocarcinoma in primary sclerosing cholangitis: a meta-analysis","volume":"6","author":"Satiya","year":"2020","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib296","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/hep.510280316","article-title":"Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography","volume":"28","author":"Keiding","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib297","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.gassur.2003.10.003","article-title":"Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma","volume":"8","author":"Anderson","year":"2004","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib298","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/hep.21433","article-title":"Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation","volume":"44","author":"Prytz","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib299","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2005.03.016","article-title":"Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"43","author":"Fevery","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib300","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00268-017-4192-3","article-title":"Diagnostic and prognostic role of 18-FDG PET\/CT in the management of resectable biliary tract cancer","volume":"42","author":"Ma","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib301","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0016-5085(95)90462-X","article-title":"Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis","volume":"108","author":"Ramage","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib302","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cgh.2011.02.007","article-title":"Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma","volume":"9","author":"Sinakos","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib303","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.gie.2013.09.015","article-title":"Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"79","author":"Trikudanathan","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib304","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/apt.13817","article-title":"Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis","volume":"44","author":"Njei","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib305","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/00365521.2017.1385840","article-title":"Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation","volume":"53","author":"Majeed","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib306","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jgh.13824","article-title":"Role of fluorescence in situ hybridization in diagnosing cholangiocarcinoma in indeterminate biliary strictures","volume":"33","author":"Liew","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib307","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1478-3231.2011.02672.x","article-title":"Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity","volume":"32","author":"Halme","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib308","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/liv.13276","article-title":"Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis","volume":"37","author":"Vannas","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib309","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.gie.2013.11.001","article-title":"Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"79","author":"Navaneethan","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib310","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ajg.2014.433","article-title":"Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis","volume":"110","author":"Eaton","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib311","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep4.1730","article-title":"DNA methylation markers for detection of cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma","volume":"5","author":"Yang","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.05.011_bib312","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gutjnl-2018-317817","article-title":"Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures","volume":"69","author":"Singhi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib313","article-title":"Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis","author":"von Seth","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib314","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/ajg.2011.272","article-title":"Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma","volume":"106","author":"Barr Fritcher","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104231","article-title":"Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis","volume":"64","author":"Waldthaler","year":"2021","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jhep.2022.05.011_bib316","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.gie.2013.05.020","article-title":"Clinical utility of EUS before cholangioscopy in the evaluation of difficult biliary strictures","volume":"78","author":"Nguyen","year":"2013","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib317","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.gie.2014.09.017","article-title":"Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib318","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00535-012-0652-6","article-title":"The role of peroral video cholangioscopy in patients with IgG4-related sclerosing cholangitis","volume":"48","author":"Itoi","year":"2013","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib319","article-title":"Digital single-operator cholangioscopy (DSOC) improves interobserver agreement (IOA) and accuracy for evaluation of indeterminate biliary strictures: the Monaco classification","author":"Sethi","year":"2020","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/a-1061-7067","article-title":"Limited diagnostic accuracy and clinical impact of single-operator peroral cholangioscopy for indeterminate biliary strictures","volume":"52","author":"de Vries","year":"2020","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2022.05.011_bib321","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1007\/s10620-013-2608-y","article-title":"ERCP with probe-based confocal laser endomicroscopy for the evaluation of dominant biliary stenoses in primary sclerosing cholangitis patients","volume":"58","author":"Heif","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.gie.2021.03.027","article-title":"Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial","author":"Han","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib323","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1432-2277.2010.01108.x","article-title":"Liver transplantation for cholangiocarcinoma","volume":"23","author":"Rosen","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib324","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/liv.14326","article-title":"Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps","volume":"40","author":"van Erp","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib325","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ajg.2011.361","article-title":"Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis","volume":"107","author":"Eaton","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib326","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/hpb.12450","article-title":"Hilar cholangiocarcinoma: expert consensus statement","volume":"17","author":"Mansour","year":"2015","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2022.05.011_bib327","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib328","series-title":"Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study","author":"Jansson","year":"2021"},{"key":"10.1016\/j.jhep.2022.05.011_bib329","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/00365521.2010.533384","article-title":"Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results","volume":"46","author":"Friman","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib330","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000658-198804000-00002","article-title":"Liver transplantation for malignant disease. Results in 93 consecutive patients","volume":"207","author":"O'Grady","year":"1988","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib331","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.transproceed.2008.08.039","article-title":"Liver transplantation for hilar cholangiocarcinoma: a German survey","volume":"40","author":"Kaiser","year":"2008","journal-title":"Transpl Proc"},{"key":"10.1016\/j.jhep.2022.05.011_bib332","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/lt.20512","article-title":"Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience","volume":"11","author":"Ghali","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib333","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/TP.0b013e31821aba57","article-title":"Outcomes and diagnostic challenges posed by incidental cholangiocarcinoma after liver transplantation","volume":"91","author":"Ali","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2022.05.011_bib334","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib335","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/SLA.0000000000002574","article-title":"Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease","volume":"267","author":"Ethun","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib336","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib337","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156127","article-title":"Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival","volume":"11","author":"Mantel","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.05.011_bib338","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","author":"Cambridge","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib339","series-title":"Pathology and Genetics of Tumours of the Digestive System","author":"Hamilton","year":"2000"},{"key":"10.1016\/j.jhep.2022.05.011_bib340","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/modpathol.3800788","article-title":"Biliary\u00a0intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria","volume":"20","author":"Zen","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2022.05.011_bib341","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.3748\/wjg.v25.i31.4343","article-title":"Common features between neoplastic and preneoplastic lesions of the\u00a0biliary tract and the pancreas","volume":"25","author":"Zaccari","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib342","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAS.0b013e3181bc96f9","article-title":"Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma","volume":"34","author":"Lewis","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2022.05.011_bib343","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jhep.2006.05.010","article-title":"Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis","volume":"45","author":"Boberg","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib344","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1572-0241.2006.00947.x","article-title":"Abnormal hepatic biochemistries in patients with inflammatory bowel disease","volume":"102","author":"Mendes","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib345","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.35.1.84","article-title":"Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm","volume":"35","author":"Broome","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib346","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3748\/wjg.14.331","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease","volume":"14","author":"Saich","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib347","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2017.09.008","article-title":"Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease","volume":"69","author":"Bosch","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2022.05.011_bib348","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib349","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis","volume":"21","author":"de Vries","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209352","article-title":"Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients","volume":"13","author":"Kumagai","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.05.011_bib351","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib352","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ibd.21699","article-title":"Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients","volume":"18","author":"Jorgensen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib353","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mge.2002.125367","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis","volume":"56","author":"Soetikno","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhep.2022.05.011_bib354","first-page":"1404","article-title":"Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential","volume":"22","author":"Broome","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib355","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies","volume":"28","author":"Zheng","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib356","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/liv.13548","article-title":"Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977-2011","volume":"38","author":"Sorensen","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib357","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/ibd\/izz209","article-title":"Unique phenotypic characteristics and clinical course in patients with ulcerative colitis and primary sclerosing cholangitis: a multicenter US experience","volume":"26","author":"Wang","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib358","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/BF02049156","article-title":"Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis","volume":"38","author":"Broome","year":"1995","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jhep.2022.05.011_bib359","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib360","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/00365521.2012.685754","article-title":"Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study","volume":"47","author":"Jorgensen","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib361","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1055\/a-1671-6336","article-title":"Endoscopic tissue sampling - Part 2: lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"53","author":"Pouw","year":"2021","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2022.05.011_bib362","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib363","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF02258391","article-title":"Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study","volume":"40","author":"Lundqvist","year":"1997","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jhep.2022.05.011_bib364","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1440-1746.2005.03727.x","article-title":"Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis","volume":"20","author":"Moayyeri","year":"2005","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib365","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/ibd\/izy106","article-title":"The natural history\u00a0of\u00a0newly diagnosed ulcerative colitis in patients with concomitant primary sclerosing cholangitis","volume":"24","author":"Khan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib366","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cgh.2018.01.020","article-title":"Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis","volume":"16","author":"Ricciuto","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib367","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","article-title":"Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon","volume":"16","author":"Krugliak Cleveland","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib368","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.13516","article-title":"Patients with large-duct primary sclerosing cholangitis\u00a0and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD","volume":"43","author":"Fevery","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib369","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ibd\/izz325","article-title":"Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes","volume":"26","author":"Peverelle","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib370","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.cgh.2018.01.023","article-title":"High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"16","author":"Shah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib371","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1053\/j.gastro.2007.08.001","article-title":"Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study","volume":"133","author":"Gupta","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib372","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib373","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib374","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/apt.13897","article-title":"The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease","volume":"45","author":"Carrat","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib375","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.dld.2018.02.014","article-title":"Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series","volume":"50","author":"Altwegg","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib376","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ecco-jcc\/jjx057","article-title":"Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis","volume":"11","author":"Westerouen van Meeteren","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib377","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.crohns.2014.08.012","article-title":"European evidence based consensus on surgery for ulcerative colitis","volume":"9","author":"Oresland","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib378","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10350-004-6255-4","article-title":"Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study","volume":"45","author":"Befrits","year":"2002","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jhep.2022.05.011_bib379","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gut.52.8.1127","article-title":"Ten year follow up of ulcerative colitis patients with and without low grade dysplasia","volume":"52","author":"Lim","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib380","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1016\/j.crohns.2013.06.006","article-title":"Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance","volume":"7","author":"Navaneethan","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib381","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.crohns.2013.02.002","article-title":"Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"7","author":"Venkatesh","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib382","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cgh.2016.11.025","article-title":"Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis","volume":"15","author":"Fumery","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib383","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1572-0241.2002.05610.x","article-title":"The fate of low grade dysplasia in ulcerative colitis","volume":"97","author":"Ullman","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib384","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/0016-5085(94)90216-X","article-title":"Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis","volume":"107","author":"Connell","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.05.011_bib385","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ecco-jcc\/jjab025","article-title":"Systematic review and meta-analysis of outcomes after ileal pouch-anal anastomosis in primary sclerosing cholangitis and ulcerative colitis","volume":"15","author":"Barnes","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib386","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.cgh.2016.11.036","article-title":"Risk of rectal cancer after colectomy for patients with ulcerative colitis: a national cohort study","volume":"15","author":"Abdalla","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib387","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/ibd\/izx048","article-title":"Restorative surgery in patients with primary sclerosing cholangitis and ulcerative colitis following a colectomy","volume":"24","author":"Nordenvall","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib388","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.3748\/wjg.v23.i33.6147","article-title":"Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis","volume":"23","author":"Boyd","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib389","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00423-014-1214-6","article-title":"Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era","volume":"399","author":"Klose","year":"2014","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib390","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0037-1608655","article-title":"Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis","volume":"37","author":"Martin","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib391","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/TP.0000000000003542","article-title":"Characteristics, trends and outcomes of liver transplantation for primary sclerosing cholangitis in female vs male patients: an analysis from the European liver transplant registry","volume":"105","author":"Berenguer","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2022.05.011_bib392","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/00365521.2015.1036359","article-title":"Liver transplantation in the Nordic countries - an intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013","volume":"50","author":"Fosby","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib393","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 Annual report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib394","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/jlts.2003.50169","article-title":"Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list","volume":"9","author":"Brandsaeter","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib395","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/ctr.12506","article-title":"Liver transplantation arrests and reverses muscle wasting","volume":"29","author":"Bergerson","year":"2015","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib396","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib397","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/lt.22396","article-title":"Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era","volume":"17","author":"Goldberg","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib398","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3109\/00365521.2015.1028996","article-title":"Primary sclerosing cholangitis - the Norwegian experience","volume":"50","author":"Schrumpf","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib399","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113157","article-title":"Selected patients with unresectable perihilar cholangiocarcinoma (pCCA) derive long-term benefit from liver transplantation","volume":"12","author":"Azad","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2022.05.011_bib400","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver transplantation for peri-hilar cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib401","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1245\/s10434-020-09001-8","article-title":"Eligibility for liver transplantation in patients with perihilar cholangiocarcinoma","volume":"28","author":"Vugts","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2022.05.011_bib402","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib403","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib404","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3748\/wjg.v18.i1.1","article-title":"Recurrence and rejection in liver transplantation for primary sclerosing cholangitis","volume":"18","author":"Fosby","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib405","first-page":"Cd005161","article-title":"Cyclosporin versus tacrolimus for liver transplanted patients","author":"Haddad","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2022.05.011_bib406","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/tri.12513","article-title":"Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis","volume":"28","author":"Pandanaboyana","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib407","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-6143.2005.01173.x","article-title":"Surgical complications and long-term outcome of different biliary reconstructions in liver transplantation for primary sclerosing cholangitis-choledochoduodenostomy versus choledochojejunostomy","volume":"6","author":"Schmitz","year":"2006","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib408","first-page":"127","article-title":"Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection?","volume":"1","author":"Lerut","year":"1988","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib409","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep.510290427","article-title":"Recurrence of primary sclerosing cholangitis following liver transplantation","volume":"29","author":"Graziadei","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib410","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/tri.13925","article-title":"Recurrence of primary sclerosing cholangitis after liver transplantation - analysing the European Liver Transplant Registry and beyond","volume":"34","author":"Visseren","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib411","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/lt.24350","article-title":"Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis","volume":"22","author":"Hildebrand","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib412","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/lt.21679","article-title":"A\u00a0re-evaluation of the risk factors for the recurrence of primary\u00a0sclerosing cholangitis in liver allografts","volume":"15","author":"Alabraba","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib413","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","article-title":"Risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"63","author":"Ravikumar","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib414","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00365521.2017.1421705","article-title":"Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study","volume":"53","author":"Lindstr\u00f6m","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","article-title":"The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis","volume":"33","author":"Joshi","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib416","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0037-1608801","article-title":"The microbiome in primary sclerosing cholangitis: current evidence and potential concepts","volume":"37","author":"Hov","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib417","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/tri.13692","article-title":"Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant - a pilot study","volume":"33","author":"Visseren","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib418","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after\u00a0transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib419","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.jhep.2022.05.011_bib420","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/2050640619858050","article-title":"Safety of vedolizumab in liver transplant recipients: a systematic review","volume":"7","author":"Spadaccini","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2022.05.011_bib421","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2012.12.027","article-title":"Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease","volume":"11","author":"J\u00f8rgensen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib422","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/ajt.14507","article-title":"Decreasing incidence of cancer after liver transplantation-A Nordic population-based study over 3 decades","volume":"18","author":"Nordin","year":"2018","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib423","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jpeds.2019.11.028","article-title":"Seamless management of juvenile autoimmune liver disease: long-term medical and social outcome","volume":"218","author":"Di Giorgio","year":"2020","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jhep.2022.05.011_bib424","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib425","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.clinre.2013.05.014","article-title":"Diagnosis of sclerosing cholangitis in children: blinded, comparative study of magnetic resonance versus endoscopic cholangiography","volume":"37","author":"Rossi","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib426","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/hep4.1454","article-title":"Magnetic resonance cholangiopancreatography severity predicts disease outcomes in pediatric primary sclerosing cholangitis: a reliability and validity study","volume":"4","author":"Patil","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.05.011_bib427","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib428","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2022.05.011_bib429","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4254\/wjh.v11.i1.19","article-title":"Treatment of primary sclerosing cholangitis in children","volume":"11","author":"Laborda","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib430","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11894-018-0620-2","article-title":"The IBD and PSC phenotypes of PSC-IBD","volume":"20","author":"Ricciuto","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhep.2022.05.011_bib431","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.dld.2008.01.017","article-title":"Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease","volume":"40","author":"Canani","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib432","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/MPG.0000000000001749","article-title":"Cholangiocarcinoma among children and adolescents: a review of the literature and surveillance, epidemiology, and end results Program database analysis","volume":"66","author":"Newsome","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2022.05.011_bib433","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/apt.14893","article-title":"Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN","volume":"48","author":"Joosse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.05.011_bib434","doi-asserted-by":"crossref","first-page":"j3951","DOI":"10.1136\/bmj.j3951","article-title":"Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014","volume":"358","author":"Olen","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2022.05.011_bib435","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cld.637","article-title":"Looking after young people with liver conditions: understanding chronic illness management in the context of adolescent development","volume":"9","author":"Darcy","year":"2017","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jhep.2022.05.011_bib436","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1542\/peds.110.S3.1304","article-title":"A\u00a0consensus statement on health care transitions for young adults with special health care needs","volume":"110","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhep.2022.05.011_bib437","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e3718","article-title":"Bridging the gap: an integrated paediatric to adult clinical service for young adults with kidney failure","volume":"344","author":"Harden","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2022.05.011_bib438","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/ajt.13184","article-title":"Pediatric liver transplant recipients who undergo transfer to the adult healthcare service have good long-term outcomes","volume":"15","author":"Sagar","year":"2015","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib439","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/lt.24629","article-title":"Liver transplantation and adolescence: the role of mental health","volume":"22","author":"Hames","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2022.05.011_bib440","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-0038-1676099","article-title":"Primary sclerosing cholangitis and psychological wellbeing: a scoping review","volume":"39","author":"Ranieri","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib441","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7861\/clinmed.2019-0172","article-title":"Paediatric to adult liver transition services: the state of play in the UK","volume":"19","author":"Joshi","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jhep.2022.05.011_bib442","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0140-6736(09)61495-1","article-title":"Liver disease in pregnancy","volume":"375","author":"Joshi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.05.011_bib443","article-title":"Reproductive health and liver disease: practice guidance by the American Association for the Study of Liver Diseases","author":"Sarkar","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib444","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/gut.2010.228924","article-title":"Pregnancy in primary sclerosing cholangitis","volume":"60","author":"Wellge","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib445","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2013.07.011","article-title":"A\u00a0population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis","volume":"12","author":"Ludvigsson","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib446","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1600-0676.1996.tb00754.x","article-title":"Pregnancy in patients with primary sclerosing cholangitis","volume":"16","author":"Janczewska","year":"1996","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2022.05.011_bib447","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/1471-0528.16119","article-title":"Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study","volume":"127","author":"Cauldwell","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.jhep.2022.05.011_bib448","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.05.011_bib449","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/SLA.0b013e318250caa9","article-title":"Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study","volume":"256","author":"Bartels","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2022.05.011_bib450","article-title":"The risk of adverse neonatal outcomes with maternal inflammatory bowel disease: a systematic review and meta-analysis","author":"Leung","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2022.05.011_bib451","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2019.08.020","article-title":"Ursodeoxycholic acid in pregnancy?","volume":"71","author":"de Vries","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib452","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10620-016-4383-z","article-title":"Contraceptive considerations for women with gastrointestinal disorders","volume":"62","author":"Sridhar","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib453","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1089\/jwh.2016.6191","article-title":"Updated guidance for safe and effective use of contraception","volume":"25","author":"Tepper","year":"2016","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.jhep.2022.05.011_bib454","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/00365520410003434","article-title":"Fatigue in patients with primary sclerosing cholangitis","volume":"39","author":"Bjornsson","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.05.011_bib455","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/liv.12775","article-title":"Health-related quality of life among patients with primary sclerosing cholangitis","volume":"35","author":"Haapamaki","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib456","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s10620-015-4013-1","article-title":"Factors that influence health-related quality of life in patients with primary sclerosing cholangitis","volume":"61","author":"Cheung","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.05.011_bib457","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1567","article-title":"A\u00a0systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis","author":"Kim","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.05.011_bib458","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/MEG.0000000000000223","article-title":"Pruritus is associated with severely impaired quality of life in patients with primary sclerosing cholangitis","volume":"26","author":"Gotthardt","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.05.011_bib459","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12955-020-01438-5","article-title":"Patient and clinician opinions of patient reported outcome measures (PROMs) in the management of patients with rare diseases: a qualitative study","volume":"18","author":"Aiyegbusi","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jhep.2022.05.011_bib460","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.29664","article-title":"Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: the PSC PRO","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.05.011_bib461","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/liv.12730","article-title":"Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis","volume":"35","author":"Raszeja-Wyszomirska","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib462","series-title":"UK-PSC quality of life update","year":"2019"},{"key":"10.1016\/j.jhep.2022.05.011_bib463","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/liv.13591","article-title":"Complications, symptoms, quality of life and pregnancy in cholestatic liver disease","volume":"38","author":"Zakharia","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.05.011_bib464","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234624","article-title":"The Primary Sclerosing Cholangitis (PSC) Wellbeing Study: understanding psychological distress in those living with PSC and those who support them","volume":"15","author":"Ranieri","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.05.011_bib465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2023.09.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822003269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822003269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T08:03:08Z","timestamp":1700726588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822003269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":465,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0168827822003269"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.05.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL Clinical Practice Guidelines on sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}